Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.50 |
| ▸ | PPARA | Q07869 | 14/20 | 0.49 |
| ▸ | PPARG | P37231 | 11/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860779 | 0.91 | PPARD (0.59) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL4861815 | 0.88 | FFAR1 (0.55) | PPARDPPARAPPARGFFAR1KDM4E | |
| SCHEMBL4852707 | 0.86 | PPARD (0.47) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL4853443 | 0.84 | PPARD (0.59) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL4853525 | 0.82 | FFAR1 (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5692529 | 0.82 | PPARD (0.54) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL5692526 | 0.82 | PPARD (0.54) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL4853039 | 0.82 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL4853534 | 0.82 | PPARD (0.70) | PPARDPPARAPPARGFFAR1MEN1 | |
| SCHEMBL4854263 | 0.80 | PPARD (0.65) | PPARDPPARAPPARGFFAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345067-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1636198-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111020-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.